OKUR Key Statistics, Chart & Performance
The current stock price of OKUR is 2.4 USD. In the past month the price decreased by -13.67%. In the past year, price decreased by -58.97%.
OKUR Technical Analysis
OKUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OKUR. No worries on liquidiy or solvency for OKUR as it has an excellent financial health rating, but there are worries on the profitability.
OKUR Financial Highlights
Over the last trailing twelve months OKUR reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 61.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.5% | ||
| ROE | -122.25% | ||
| Debt/Equity | 0 |
OKUR Forecast & Estimates
12 analysts have analysed OKUR and the average price target is 26.01 USD. This implies a price increase of 983.75% is expected in the next year compared to the current price of 2.4.
OKUR Ownership
OKUR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.96 | 398.827B | ||
| AMGN | AMGEN INC | 16.25 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 12.01 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OKUR
Company Profile
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 46 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Company Info
ONKURE THERAPEUTICS INC-A
6707 Winchester Circle, Suite 400
Boulder COLORADO US
Employees: 46
Phone: 17203072892
ONKURE THERAPEUTICS INC-A / OKUR FAQ
Can you describe the business of ONKURE THERAPEUTICS INC-A?
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 46 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
What is the current price of OKUR stock?
The current stock price of OKUR is 2.4 USD.
What is the dividend status of ONKURE THERAPEUTICS INC-A?
OKUR does not pay a dividend.
What is the ChartMill technical and fundamental rating of OKUR stock?
OKUR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ONKURE THERAPEUTICS INC-A (OKUR) stock?
12 analysts have analysed OKUR and the average price target is 26.01 USD. This implies a price increase of 983.75% is expected in the next year compared to the current price of 2.4.
Can you provide the market cap for ONKURE THERAPEUTICS INC-A?
ONKURE THERAPEUTICS INC-A (OKUR) has a market capitalization of 32.52M USD. This makes OKUR a Nano Cap stock.
Can you provide the upcoming earnings date for ONKURE THERAPEUTICS INC-A?
ONKURE THERAPEUTICS INC-A (OKUR) will report earnings on 2026-03-09, after the market close.